SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-225456
Filing Date
2022-08-19
Accepted
2022-08-19 17:23:20
Documents
13
Period of Report
2022-08-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d384340d8k.htm   iXBRL 8-K 26775
2 EX-10.1 d384340dex101.htm EX-10.1 58746
  Complete submission text file 0001193125-22-225456.txt   214625

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA halo-20220818.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE halo-20220818_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE halo-20220818_pre.xml EX-101.PRE 10815
7 EXTRACTED XBRL INSTANCE DOCUMENT d384340d8k_htm.xml XML 3230
Mailing Address 11388 SORRENTO VALLEY ROAD SAN DIEGO CA 92121-1345
Business Address 11388 SORRENTO VALLEY ROAD SAN DIEGO CA 92121-1345 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

IRS No.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 221181636
SIC: 2836 Biological Products, (No Diagnostic Substances)